Aritinercept
Based on 1 Customer Validation
Aritinercept (AUR-200) is a recombinant fusion protein targeting TNFSF13B/BAFF/CD257. Aritinercept neutralizes BAFF and APRIL (TNFSF13), reduces B cell proliferation, suppresses peripheral B cells, lowers serum immunoglobulins. Aritinercept reduces renal damage markers, decreases IFNγ, IL-17A, and anti-dsDNA autoantibodies, and improves survival in a mouse model of SLE. ritinercept can be used for the research of systemic lupus erythematosus.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.9%
- No. CAS: 3057276-00-0
- Peso molecular:61.925 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Species Reactivity
Human
IC50 & Target
[1]|
IL-17A |
In Vitro
Aritinercept exhibits high binding affinity (Kd) to human BAFF (117 pM), human APRIL (25 pM), mouse BAFF (31 pM), and mouse APRIL (505 pM) in a cell-free surface plasmon resonance binding assay[1].
Aritinercept potently inhibits human APRIL (IC50 = 0.002 nM), mouse BAFF (IC50 = 1.5 nM), and mouse APRIL (IC50 = 2.7 nM) in a cell-free competitive ELISA, with no detectable inhibition of human BAFF[1].
Aritinercept reduces BAFF and APRIL-costimulated proliferation of human primary B cells and mouse splenocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Aritinercept (1 mg/kg; s.c.; single dose) suppresses peripheral B cells, and (5-80 mg/kg; s.c.; weekly; 4 weeks) induces sustained reductions in all serum immunoglobulins in healthy cynomolgus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NZBxNZW F1 (randomized by body weight and proteinuria scores)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:s.c.; weekly; 6 weeks
-
Result:Significantly improved survival at all doses tested.
Reduced proteinuria.
Decreased histological markers of renal damage.
Significantly decreased serum IFNγ and IL-17A levels at all doses.
Dose-dependently reduced serum anti-dsDNA autoantibodies.
-
Animal Model:Cynomolgus monkeys[1]
-
Dosage:1 mg/kg; 5 mg/kg; 20 mg/kg; 80 mg/kg
-
Administration:s.c.; single dose (1 mg/kg); weekly; 4 weeks (5, 20, 80 mg/kg)
-
Result:Suppressed peripheral B cells (single 1 mg/kg subcutaneous dose).
Induced sustained reductions in all serum immunoglobulins (weekly subcutaneous doses of 5, 20, or 80 mg/kg for 4 weeks).
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- How to Choose the Right Model Animal
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
Gene ID
Accession
Target
TNFSF13B/BAFF/CD257
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
FPIA_[PROTEIN]2-FC
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Aritinercept. The ED50 for this effect is 0.5949 ng/mL.
Chemical Information
-
No. CAS 3057276-00-0
-
Appearance Liquid
-
Peso molecular 61.925 kDa
-
Color Colorless to light yellow
-
SMILES
[Aritinercept]
-
Synonyms
AUR-200
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Aritinercept
- 3057276-00-0
- AUR-200
- AUR200
- AUR 200
- TNF Receptor
- IFNAR
- Interleukin Related
- Tumor Necrosis Factor Receptor
- TNFR
- Interferon-α/β receptor
- Interferon-alpha/beta receptor
- IL
- IFNγ
- IL-17A
- systemic lupus erythematosus
- renal damage markers
- anti-dsDNA autoantibodies
- B cell proliferation
- serum immunoglobulins
- peripheral B cells
- BAFF
- APRIL
- Inhibitor
- inhibitor
- inhibit